Abstract. Cancer metastasis and relapse are the primary cause of mortality for patients with breast cancer. The present study performed quantitative proteomic analysis on the differentially expressed proteins between highly metastatic breast cancer cells and parental cells. It was revealed that forkhead box P2 (FOXP2), a transcription factor in neural development, may become a potential inhibitor of breast cancer metastasis. The results demonstrated that patients with a lower level of FOXP2 expression had significantly poorer relapse-free survival (P=0.0047). The transcription of FOXP2 was also significantly downregulated in breast cancer tissue compared with normal breast tissue (P=0.0005). In addition, FOXP2 may inhibit breast cancer cell migration and invasion in vitro. It was also revealed that the underlying mechanism may include the epithelial-mesenchymal transition process driven by the tumor growth factor β/SMAD signaling pathway. In conclusion, the present study identified FOXP2 as a novel suppressor and prognostic marker of breast cancer metastasis. These results may provide further insight into breast cancer prevention and the development of novel treatments.
Introduction
Breast cancer remains one of the most prevalent types of cancer among women. It is estimated that there will be 255,180 new breast cancer cases and 41,070 deaths in the U.S. in 2017 (1) . Most of the mortality is caused by cancer invasion and metastasis. However, there are still limited effective therapies for metastatic breast cancer patients. In our previous study, we investigated the differentially expressed proteins between parental MDA-MB-231 and highly metastatic MDA-MB-231 (MDA-MB-231HM and MDA-MB-231BO) breast cancer cell lines (2) (3) (4) . We found that forkhead box P2 (FOXP2), a transcription factor, had a significantly reduced expression level in highly metastatic cell lines. FOXP2 is a member of FOXP gene subfamily (FOXP1, FOXP2, FOXP3, FOXP4) which all have a C-terminal winged helix forkhead DNA binding domain. The structure is conserved in many species. It was previously proved that the gene FOXP2, locating at 7q31, regulates many neurogenesis signaling pathways critical in embryonic development and cell cycle such as Hedgehog, WNT and Notch pathways (5, 6) . It is also involved in lung, heart and central nervous system (CNS) development. Especially, it plays pivotal roles in human language development. Depletion and mutation in FOXP2 can lead to speech and linguistic impairment, aging and cancer (7, 8) .
Several researches have also reported the roles of FOXP2 as a tumor suppressor in gastric cancer (9) , osteosarcoma (10) and hepatocellular carcinoma (11) previously. It was revealed that the expression of FOXP2 was usually regulated by a series of microRNAs in cancer cells. However, there were not many studies investigating the mechanisms of FOXP2 in breast cancer. In our current study, we explored the effects and mechanisms of FOXP2 on breast cancer metastasis and prognosis. We hope our study could provide deeper insights into the diagnosis and treatment of metastatic breast cancer.
Materials and methods
Tumor samples. Our study has already been approved by the Ethical Committee and Institutional Review Board of Fudan University Shanghai Cancer Centre (FDUSCC). The methods were performed in accordance with the approved guidelines. All the participants signed written informed consent forms. (12) . The primer sequences used in this study are as follows: FOXP2: forward 5'-AAC AAC AGC AGG CTC TCC AG-3' , and reverse 5'-GGC ACC TGC AGT GGT CTC-3'; GAPDH: forward 5'-GGT GGT CTC CTC TGA CTT CAA CA-3' , and reverse 5'-GTT GCT GTA GCC AAA TTC GTT GT-3'.
Cell culture. The cells in this study were obtained from the Shanghai Cell Bank, Type Culture Collection Committee of Chinese Academy of Science (Shanghai, China). The cells for experiments were passaged for less than 6 months. MDA-MB-231, MDA-MB-231BO, MDA-MB-231HM and MDA-MB-468 (all triple negative breast cancer) cells were grown in Leibovitz L-15 medium (BasalMedia, Shanghai, China). 293T, MCF7 (luminal positive breast cancer) and BT549 (triple-negative breast cancer) cells were cultured in high-glucose Dulbecco's modified Eagle's medium (DMEM; HyClone; GE Healthcare Life Sciences, Logan, UT, USA). SKBR3 (HER2 positive breast cancer), T47D, ZR7530 and ZR75-1 (all luminal positive breast cancer) were maintained in RMPI-1640 medium (HyClone; GE Healthcare Life Sciences). All the medium was supplemented with 10% FBS, 100 IU/ml penicillin, and 100 mg/ml streptomycin. All the cells were maintained with 5% CO 2 at 37˚C. The MDA-MB-231HM was developed from the parental MDA-MB-231 cell line via the tail vein in mice for four cycles. We have patent application for the cell line (patent no. 200910174455.4) which exhibited increased lung metastasis compared to parental cells. The MDA-MB-231BO cells, which have highly metastatic potential to bone, was obtained from Dr Toshiyuki Yoneda (University of Texas, Houston, TX, USA). We have done several studies with these cell lines (4, 13) .
Plasmids and lentivirus packaging. Human FOXP2 cDNA was purchased from fulenGen and then subcloned into the pCDH-CMV-MCS-EF1-Puro lentiviral vector. The cloned primer sequence is as follows: FOXP2: forward 5'-CCG GAA TTC GCC ACC ATG ATG CAG GAA TCT GCG AC-3', and reverse 5'-CGC GGA TCC TCA TTC CAG ATC TTC AGA TA-3'.
FOXP2 shRNAs and the negative control were purchased from GeneChem and expressed in the GV248 backbone. The target sequences are as follows: shRNA NC 5'-TTC TCC GAA CGT GTC ACG T-3'; shRNA1: 5'-TTA ACA ATG AAC ACG CAT T-3'; shRNA2: 5'-AGC AAA CAA GTG GAT TGA A-3'.
293T cells were cotransfected with lentiviral vectors and the packaging vectors pCDH (GV248), psPAX2 and pMD2G. Virus-containing medium was collected 48 h after the transfection and added to the cancer cells.
Kinetic wound-healing assay. MDA-MB-231 and MDA-MB-231BO cells (3.6x10 4 ) were plated on 96-well plates (Essen ImageLock; Essen Biosciences, Ann Arbor, MI, USA), and a wound was scratched with wound scratcher (Essen Instruments). Wound confluence was monitored with Live-Cell Imaging System and software (Essen Biosciences). The wound closure was observed after 28 h by comparing the mean relative wound density of at least three biological replicates in each experiment.
Transwell assay. Cell migration and invasion was examined with Transwell chambers (BD Biosciences, Franklin Lakes, NJ, USA). The cells were seeded in the upper chamber in serum-free medium. The cell density was 5x10 5 for migration assay and 1x10 6 for Matrigel-coated invasion assay. Medium supplemented with 20% serum was added in the lower chamber. The cells were incubated for 15 to 20 h. After that, the cells remained on the upper chamber were removed with cotton swabs. The cells on the lower surface of the membrane were stained with 0.4% methanol and 0.25% crystal violet.
Western blot analysis.
Whole cell extracts were isolated with Pierce T-PER (Tissue Protein Extraction Reagent; Thermo Fisher Scientific, Inc.) containing protease inhibitor cocktail tablets (Roche Diagnostics, Indianapolis, IN, USA) and phosphatase inhibitors (Roche Diagnostics). Proteins (30 µg) were resolved by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto a polyvinylidene fluoride membrane (Pall Corporation, Port Washington, NY, USA). The membranes were blocked in 5% BSA and incubated in various primary antibodies followed by the corresponding horseradish peroxidase-conjugated secondary antibodies (Proteintech Group, Inc., Chicago, IL, USA). The primary antibody against FOXP2 (21608) and vimentin (40477) Statistical analysis. SPSS 22.0 software (IBM Corp., Armonk, NY, USA) was used to conduct the statistical analysis. Data were expressed as means ± standard deviation. The student's t-test was used to evaluate the differences between two groups and one-way analysis of variance (ANOVA) was used among multiple groups. LSD test was used after ANOVA to compare the differences between two groups. P<0.05 was considered to indicate a statistically significant difference. Graphs were created with GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA, USA).
Results

Low expression of FOXP2 indicated poorer prognosis in breast
cancer. The information of FOXP2 expression and patients' survival was acquired from an online Kaplan-Meier plotter (http://kmplot.com/analysis/). This online tool was based on data of 1,809 patients downloaded from GEO (Affymetrix HGU133A and HGU133+2 microarrays) (14) . The low and high expression was divided by median expression. In Kaplan Meier analysis (Fig. 1) , the expression level of FOXP2 was significantly correlated to the patients' relapse-free survival (RFS, P=0.0047, HR=0.79; Fig. 1B ), but not to overall survival (OS, P=0.18, Fig. 1A ). Among patients with different molecular subtypes, low FOXP2 expression only predicted higher risk of relapse among luminal A (P=0.0037) and basal-like breast cancer patients (P=0.014). The results suggested that low expression of FOXP2 may be associated with recurrence and metastasis in some breast cancer patients.
FOXP2 expression was downregulated in breast cancer
compared to normal breast tissue. According to the data from oncomine (www.oncomine.org), the expression of FOXP2 was significantly lower in breast cancer than normal breast tissue (P<0.001; Fig. 2A ). The results remained same both in invasive ductal carcinoma and invasive lobular carcinoma ( Fig. 2B and C) . However, there was no significant difference among patients with and without metastasis (Fig. 2D) . We also evaluate the expression level of FOXP2 in different breast cancer cell lines (Fig. 2E and F) as well as 39 patients' samples (Fig. 2G) . Interestingly, FOXP2 was significantly less expressed in breast cancer tissue compared to adjacent control tissue (P=0.0005). The results were consistent with the data from the public database. Table I summarized the clinicopathological characteristics of the patients. In this cohort, the FOXP2 expression was not significantly associated with these clinical features except age.
In addition, we also investigated the frequency of FOXP2 alterations, including amplification and mutations, in breast cancer (Fig. 2H ) from cbioprotal (www.cbioportal.org) (15) . We found that among 4,786 invasive breast cancer cases from 9 studies, 144 patients had amplification (3%) and 17 (0.4%) had mutation of this gene.
FOXP2 inhibited breast cancer cells migration and invasion.
To validate the function of FOXP2 in breast cancer metastasis and proliferation, we knocked down FOXP2 in MDA-MB-231 and overexpressed it in MDA-MB-231BO and MDA-MB-231HM breast cancer cells via lentivirus infection. The efficiency of infection was confirmed by western blot analysis (Fig. 3A) . We then found that the depletion of FOXP2 did not have significant effects on cell proliferation (Fig. 3B) . But the wound-healing assay and Transwell assay showed that the knockdown of FOXP2 could promote cell migration and invasion in vitro (P=0.001; Fig. 3C and D) . Meanwhile, the cell migration and invasion was inhibited after the overexpression of FOXP2 (P<0.001). Taken together, the results suggested that FOXP2 may play a certain role in breast cancer as a tumor suppressor gene.
Suppression of FOXP2 induced EMT and activated
TGFβ/SMAD signaling pathway. Epithelial-mesenchymal transition (EMT) was known as one of crucial mechanisms in cancer progression and metastasis (16) . In order to further investigate the mechanisms of FOXP2 inhibiting breast cancer metastasis, we detected the expression level of several EMT-associated biomarkers in MDA-MB-231 and BT549 (Fig. 4A) . The results revealed that suppression of FOXP2 promoted the expression of vimentin and fibronectin in MDA-MB-231. In BT549 cell line, fibronectin and N-cadherin was inhibited after overexpression of FOXP2. The results suggested that FOXP2 could inhibit EMT in breast cancer in vitro.
The activation of TGFβ/SMAD signaling was known as one of the critical pathways in EMT process and cancer metastasis (17, 18) . Therefore, we also detected the expression of some important proteins in TGFβ signaling (Fig. 4B) . We found that upregulation of FOXP2 in BT549 could markedly decrease the phosphorylation of SMAD3, enhanced the expression of SMAD4, TGFβR1, ZEB1 and Snail. Meanwhile, suppression of the gene in MDA-MB-231 could cause the reverse effects except ZEB1. The expression of Twist and p-SMAD2 did not seem to show significant differences in the cell lines in this research. The phenomenon indicated that inhibition of FOXP2 induce EMT process in breast cancer probably via TGFβ/SMAD signaling pathway.
Discussion
The mechanisms of breast cancer invasion and metastasis are still not fully understood. In our study, we demonstrated FOXP2 might be a potential target for the prevention and treatment of breast cancer metastasis. The function of FOXP2 was initially identified in neurodevelopmental disorders, especially inherited speech-and-language disorders (19, 20) . Here, we first reported the role of FOXP2 in inhibiting EMT in breast cancer via TGFβ/SMAD signaling pathway. Upon FOXP2 depletion, the cell mesenchymal biomarkers decreased which indicated higher potential of cell motility and migration. Interestingly, we found that the TGFβ pathway related proteins (TGFβR1, p-SMAD3, SMAD4, Snail) were obviously elevated after downregulation of FOXP2. However, the detailed mechanisms of FOXP2 regulating TGFβ pathway are still unclear. TGFβ/SMAD signaling is a well-known pathway activated during cancer metastasis and transmits signals from cell surface receptors to nuclear transcription (18) . Tumor cells usually produce abundant amount of TGFβ which activates downstream SMAD2/3/4. Then the activated SMADs translocate to nucleus and activated EMT-related transcription factors including Snail, ZEB1/2, Twist, (21) . But effective drugs targeting this pathway are still limited clinically, partially because of the side effects (22) .
There have been only a few studies investigating the role of FOXP2 in cancer so far. Some studies suggested FOXP2 mediated the crosstalk between breast cancer cells and tumor-associated mesenchymal stem cells (MSCs). For example, Cuiffo et al (23, 24) reported that the expression of FOXP2 was regulated by a series of miRNA including miR-199a. They also found that FOXP2 could inhibited breast cancer initiation and colonization through inhibiting a series of cancer stem cell associated factors including c-Myc, Oct-4, CD44, etc. FOXP2 could also be regulated by miR-190 in gastric cancer (9) . Upregulation of miR-190 can cause the downregulation of FOXP2 protein expression and then lead to gastric cancer cells migration and invasion. Another study (10) observed transient overexpression of FOXP2 in pre-osteoblast mesenchymal cells influenced a p21-dependent growth arrest checkpoint, which played important roles in the growth of osteosarcoma. These results all confirmed the function of FOXP2 in tumor suppression.
There were also several limitations in our study. For example, the targeted genes regulated by FOXP2 in breast cancer was still unclear. As a transcription factor, FOXP2 need to combine the promoters of the targeted genes to regulate the downstream pathway. But we failed to find the promoters directly targeted by FOXP2. Moreover, we only involved a limited number of patients, most of which had lymph nodes invasion. We did not establish ideal tumour metastatic models in this study. Therefore, the results still need further validation in larger number of cohorts and in vivo.
In conclusion, we identified FOXP2 as a novel tumor suppressor gene in human breast cancer using clinical correlation analysis and in vitro functional metastasis assays. Drugs might be developed to mimic the functions of FOXP2 as a tumor suppressor to prevent or treat breast cancer metastasis in the future. We hope our findings could contribute to the diagnosis and treatment of breast cancer to some extent. Further studies still need to be done in order to investigate the underlying mechanisms of the functions of FOXP2 in the future. 
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